Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. haematol [Internet]. 2012Jun.4 [cited 2024Nov.22];97(6):842-8. Available from: https://haematologica.org/article/view/6321